In Memoriam: Cedric Long, Assistant Director of NCI's Division of Extramural Activities
Dr. Cedric W. Long, assistant director of NCI's Division of Extramural Activities (DEA), passed away unexpectedly on May 3; he was 75.
Dr. Long spent his 32-year federal career at NCI, including 15 years with DEA. As DEA's assistant director, he oversaw the management of NCI's advisory committees and research integrity compliance. He also served as project officer for the contract supporting operations of the presidentially appointed National Cancer Advisory Board (NCAB) and NCI's Board of Scientific Advisors. Dr. Long was an advisor to the DEA director on extramural policies, including those involving the interface between extramural, intramural, and contract operations.
Over the course of his career, Dr. Long held many leadership positions, and he published more than 90 original papers and abstracts. His research projects spanned the fields of enzymology, protein chemistry, cell biology, virology, immunology, and nucleic acid chemistry. He also studied the factors controlling the expression of leukemia and sarcoma viruses and how these factors relate to cell growth and the transformation of normal tissue into malignant tissue.
Dr. Long was a member of the American Society of Biological Chemists, the American Association for the Advancement of Science, and Sigma Xi. He served as a referee for the Journal of the National Cancer Institute, Analytical Biochemistry, International Journal of Cancer, and the National Science Foundation. Dr. Long was also a member of the NCI Cancer Bulletin Executive Editorial Committee.
A memorial service will be held on June 14 at 2:00 p.m. at the Neuroscience Center Building in conference rooms C and D, located at 6001 Executive Boulevard, in North Bethesda, MD.
NCI's Advanced Technology Research Facility Opens
On May 21, more than 700 guests attended a ribbon-cutting ceremony to mark the opening of NCI's Advanced Technology Research Facility (ATRF) in Frederick, MD. NCI's Deputy Director for Management John Czajkowski, SAIC President and CEO John Jumper, SAIC-Frederick CEO David Heimbrook, and Rep. Roscoe Bartlett (R-MD) joined representatives of the Frederick County Chamber of Commerce at the ceremony.
The event, hosted by the Chamber, was held in the three-story open atrium of the 330,000-square-foot research and development facility that will house staff from the Frederick National Laboratory for Cancer Research. The ATRF includes laboratories for studying genetics, genomics, proteomics, advanced biomedical imaging, nanotechnology, and clinical-grade drug development and manufacturing for first-in-human studies.
The facility will be a centerpiece of NCI's efforts to develop partnerships that bring together collaborators from government, industry, academia, and the nonprofit sector. These efforts can accelerate the translation of basic research findings into clinical technologies, diagnostics, and treatments for patients with cancer and AIDS. About 40,000 square feet of the interior space will be reserved for partnership projects and start-up companies coming out of the projects.
"This building is designed to facilitate collaboration," said Dr. Heimbrook, in his opening remarks. "Within a few short months, these hallways will be filled with scientists from NCI, SAIC-Frederick, and our partners, doing research and development work to further NCI's mission to provide new hope to patients afflicted with cancer and AIDS."
The work done at the ATRF will pave the way for doctors to "provide the right drug, to the right patient, at the right time," he added.
NCI and China Cancer Institute Discuss Research Issues and Medical Journalism
Scientists, clinicians, and government officials from the United States and China met earlier this month in Beijing for a workshop sponsored by NCI's Center for Global Health and the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences (CICAMS). Participants discussed research on cancer prevention, screening, and biomarkers. At the meeting, held May 9–11, speakers reviewed the status of research in both countries and explored a broad range of opportunities for future collaboration.
Other topics included cancer biomarker research for early diagnosis and prevention, NCI-supported studies of esophageal cancer in China, and U.S.-China collaborations by tumor site. NCI and Chinese government officials highlighted funding opportunities and grant procedures for cancer researchers. In addition, participants explored a proposal to translate NCI's Physician Data Query (PDQ) online summaries of cancer-related information into Chinese.
"The quality of science presented by both CICAMS and U.S. investigators was invigorating. Just as important, plans for collaborations in several areas of high priority for both countries in the areas of cancer biomarker and screening research were a major topic of discussion," said Dr. Barry Kramer, director of NCI's Division of Cancer Prevention, who attended the workshop.
CICAMS Director of Cancer Epidemiology Dr. You-Lin Qiao noted, "The extensive discussion and recommendations for community-based screening of four priority cancers (lung, esophageal, breast, and cervical cancers) provides a great collaboration opportunity for scientists of both countries in the context of China's increased investment in health-related projects."
NCI and CICAMS also hosted a May 8 workshop on medical journalism and cancer research for Chinese editors and reporters to learn how to better evaluate, interpret, and summarize cancer research topics for a lay audience. The session helped participants determine which studies are newsworthy and how to present scientific results accurately to the public.
Paula Jacobs Appointed Associate Director in NCI's Division of Cancer Treatment and Diagnosis
Dr. Paula Jacobs has been appointed associate director in NCI's Division of Cancer Treatment and Diagnosis and will be responsible for the Cancer Imaging Program. Dr. Jacobs began working at NCI after 30 years in the private sector, where she developed ultrasmall superparamagnetic iron oxide drugs as magnetic resonance imaging agents and iron replacement therapies.
Her research at NCI has focused on lowering the scientific, logistical, and regulatory barriers to investigational use of PET radiopharmaceuticals for therapeutic drug development. She works to standardize imaging techniques to make them more reliable and conducts exploratory research to correlate genomic information about tumors with tumor imaging data.
Proposals Sought for Use of PLCO Data and Biospecimens
Data and biospecimens from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial are available to qualified researchers through a peer-review process. The Etiology and Early Marker Studies (EEMS) program accepts proposals for access to PLCO biospecimens twice a year. Proposals for the next cycle will be accepted between June 1 and July 16, 2012.
By collecting biologic materials and information about risk factors from trial participants before the diagnosis of disease, EEMS—a component of the PLCO—provides a resource for cancer researchers who are studying the causes and origins of cancer and/or early detection of the disease. Etiologic studies investigate environmental, biochemical, and genetic risk factors for cancer. Early detection studies aim to develop reproducible, reliable biomarkers of early disease.
Cyber-Seminar Will Examine Cancer Control at State and Local Level
The June 12 NCI Research to Reality (R2R) cyber-seminar will feature examples of successful cancer control coalitions that have used evidence-based public health practice to implement state cancer plans in local jurisdictions.
The seminar will explore state and local health department perspectives. Bruce Behringer of the Tennessee Department of Health and Della Rhoades of Nodaway County Health Center in Missouri will share their stories of success, lessons learned, and opportunities. In addition, Brandie Adams of the National Association of County and City Health Officials will present the association's new resource guides. These guides are designed to support local implementation of comprehensive cancer control work through local, community-based coalitions.
For more information and to register for this event, visit the R2R website, where you can watch presentations and join discussions. All R2R cyber-seminars are archived on the website a week after the presentation.
For more information on the cyber-seminar series, please e-mail ResearchtoReality@mail.nih.gov.